CDK12 and Familial prostate cancer: By contrast, primary prostate cancer (PCa) sequences in The Cancer Genome Atlas (TCGA) revealed biallelic CDK12 alterations in only 6/498 cases (1.2%)—a finding indicating enrichment of CDK12 inactivation in metastatic disease.18